279 related articles for article (PubMed ID: 27259008)
1. Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy.
Urabe M; Ushiku T; Seto Y; Fukayama M
Am J Surg Pathol; 2016 Oct; 40(10):1326-33. PubMed ID: 27259008
[TBL] [Abstract][Full Text] [Related]
2. [Remarkable Response to Trastuzumab Observed in a Case of Gastric Cancer with HER2-Negative Conversion].
Horii N; Morioka D; Yamaguchi K; Sato Y
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1207-1209. PubMed ID: 27760939
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
Kijima T; Arigami T; Uenosono Y; Hiraki T; Yanagita S; Matsushita D; Okubo K; Shimonosono M; Ishigami S; Maemura K; Tanimoto A; Natsugoe S
Anticancer Res; 2020 Jan; 40(1):75-80. PubMed ID: 31892554
[TBL] [Abstract][Full Text] [Related]
4. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
5. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study.
Watson S; Validire P; Cervera P; Zorkani N; Scriva A; Lemay F; Tournigand C; Perniceni T; Garcia ML; Bennamoun M; Paye F; Louvet C
Ann Oncol; 2013 Dec; 24(12):3035-9. PubMed ID: 24114855
[TBL] [Abstract][Full Text] [Related]
6. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
7. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
[TBL] [Abstract][Full Text] [Related]
8. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
11. [A Case of HER2-Positive Stage IV Advanced Gastric Cancer Treated with Chemotherapy Combined with Trastuzumab].
Takaya K; Takahashi R; Honma S; Horii S; Takahashi H; Hagiwara M; Chin M; Hashizume E
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1113-6. PubMed ID: 27628555
[TBL] [Abstract][Full Text] [Related]
12. [A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy].
Endo S; Yamada T; Okuyama M; Hiraoka K; Konishi K; Kim C; Nakagawa T; Takeda K; Ueda Y; Matsumoto K; Nishikawa K; Nishijima J
Gan To Kagaku Ryoho; 2015 Mar; 42(3):359-61. PubMed ID: 25812508
[TBL] [Abstract][Full Text] [Related]
13. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
14. [A Case of HER2-Positive Advanced Gastric Cancer with a Pathological Complete Response to Neoadjuvant Chemotherapy with S-1/CDDP/Trastuzumab].
Nishino M; Hosoda Y; Okano M; Nagai K; Yasui M; Kim Y; Tsujinaka T
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2043-5. PubMed ID: 26805258
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
16. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
Park SR; Park YS; Ryu MH; Ryoo BY; Woo CG; Jung HY; Lee JH; Lee GH; Kang YK
Eur J Cancer; 2016 Jan; 53():42-50. PubMed ID: 26693898
[TBL] [Abstract][Full Text] [Related]
17. HER2-positive gastric cancer with paraaortic nodal metastasis successfully resected after chemotherapy with trastuzumab: a case report.
Ikari N; Nakajima G; Taniguchi K; Sasagawa T; Narumiya K; Yamada T; Kudo K; Kitamura Y; Hayashi K; Nishikawa T; Yamamoto M
Anticancer Res; 2014 Feb; 34(2):867-72. PubMed ID: 24511024
[TBL] [Abstract][Full Text] [Related]
18. [A Case of HER2-Positive Advanced Gastric Cancer with Multiple Liver Metastases Effectively Treated with Trastuzumab, Capecitabine, and Cisplatin Combination Therapy].
Kuga Y; Kitamura S; Okanobu H; Sakimoto H; Nishida T
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1211-1214. PubMed ID: 27760940
[TBL] [Abstract][Full Text] [Related]
19. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
Ohzawa H; Sakatani T; Niki T; Yasuda Y; Hozumi Y
Breast Cancer; 2014 Sep; 21(5):563-70. PubMed ID: 23108629
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
Matsushita D; Uenosono Y; Arigami T; Yanagita S; Okubo K; Kijima T; Miyazono F; Hamanoue M; Hokita S; Nakashima S; Ohtsuka T; Natsugoe S
Cancer Chemother Pharmacol; 2021 Jun; 87(6):789-797. PubMed ID: 33641065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
